A particularly aggressive form of breast cancer is known as triple negative breast cancer. The journal Oncotarget recently published a research paper detailing how it can respond to hormone therapy when it occurs that the cell has an estrogen receptor beta protein. The findings of this study also say that there are more molecules that were uncovered in the study that could be targeted by new breast cancer drugs in order to cure this disease.
— Oncotarget (@OncotargetJrnl) December 5, 2017
This type of breast cancer occurs in about 15% of those women who have been diagnosed with this disease. One of the author of the study, Dr. Hawse, said that the study was preliminary. He said that both cellular and animal models would need to be further researched prior to a clinical trial being performed. He said that this line of thought would be explored further by his team of researchers. Check Oncotarget at scimagojr.com
Oncotarget also made the news recently when they announced that they had given four biomedical researchers travel grants so that they could attend a conference in Singapore. The conference was called Frontiers in Cancer Science 2017 and it was held November 6th to the 8th. The conference had seven research institutes hosting it such as the Cancer Science Institute of Singapore and the Lee Kong Chian School of Medicine. Listen to an audio podcast of Oncotarget on Itunes.
Oncotarget is the premier peer-reviewed research journal that is focused on oncology. It was published twice a week and on an open access basis. One of the core missions of the journal is to spread information about scientific advances in the field of oncology as wide as possible. The editor-in-chief of this journal, Mikhael Blagosklonny, said that the Frontiers in Cancer Science 2017 meeting brought together some of the top minds when it comes to cancer research in the world.
Three of the researchers that Oncotarget selected came from India while one performs research in Italy. The three from India were Mohd Anas Shamsi, Ruhi Sandeep Deshmukh, and Rajni Kumari. The researcher from Italy was Vladen Milosevic who works in the Department of Oncology at the University of Torino. </a>